- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)

These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006). | |
Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records. |
Study title: A multi-centre, randomised, double-blind, placebo controlled, parallel group study of oral alendronate sodium in paediatric patients with severe osteogenesis imperfecta, followed by an open label extension. |
Active substance: ALENDRONIC ACID |
Study summary document link (including results): |
View full study record |
Document reference: 46327 |
Study title: An open label study to investigate the pharmacokinetic profile of alendronate in paediatric patients with osteogenesis imperfecta. |
Active substance: ALENDRONIC ACID |
Study summary document link (including results): |
View full study record |
Document reference: 46328 |
Study title: An Open-Labeled Study to Investigate the Pharmacokinetic Profile of Alendronate in Glucocorticoid-Treated Pediatric Patients |
Active substance: ALENDRONIC ACID |
Study summary document link (including results): |
View full study record |
Document reference: 46326 |